iCAD (NASDAQ:ICAD – Get Free Report) posted its quarterly earnings results on Wednesday. The technology company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.02, Zacks reports. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.65%.
iCAD Stock Performance
Shares of NASDAQ ICAD traded up $0.15 during trading hours on Wednesday, hitting $2.47. 388,327 shares of the stock were exchanged, compared to its average volume of 248,285. The company has a market cap of $65.55 million, a PE ratio of -19.00 and a beta of 1.95. The company’s fifty day simple moving average is $2.63 and its two-hundred day simple moving average is $2.05. iCAD has a 1-year low of $1.18 and a 1-year high of $3.78.
Analyst Ratings Changes
Separately, StockNews.com lowered shares of iCAD from a “hold” rating to a “sell” rating in a research report on Tuesday.
About iCAD
iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.
See Also
- Five stocks we like better than iCAD
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- Learn Technical Analysis Skills to Master the Stock Market
- Alphabet’s Officially In A Bear Market—Time To Buy?
- How to Calculate Inflation Rate
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.
